Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To provide an evidence-based approach to the use of therapies that are prescribed to improve the natural history of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)-a rare disease. RECENT FINDINGS: All 41 articles on the clinical outcome of disease-modifying therapy for HAM/TSP were included in a systematic review by members of the International Retrovirology Association; we report here the consensus assessment and recommendations. The quality of available evidence is low, based for the most part on observational studies, with only 1 double-masked placebo-controlled randomized trial. SUMMARY: There is evidence to support the use of both high-dose pulsed methyl prednisolone for induction and low-dose (5 mg) oral prednisolone as maintenance therapy for progressive disease. There is no evidence to support the use of antiretroviral therapy. There is insufficient evidence to support the use of interferon-α as a first-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most DMTs aim to suppress the immune response, modulate inflammation, and reduce the PVL to modify the course of disease [231].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [231]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Symptomatic management is helpful in improving patient mobility and quality of life; however, they fail to alter the course and progression of disease [231].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [231]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Inflammatory manifestations of HTLV-1 and their therapeutic options
Martin, F., Taylor, G. P., & Jacobson, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.966690 · Cited by 147 · cited 1×
“47% over a median of 3 years in 1 cohort.(2,3)”
BackgroundSelf-citationTanajura, D., Castro, N., Oliveira, P., Neto, A., Muniz, A., Carvalho, N. B., Orge, G., Santos, S., Glesby, M. J., & Carvalho, E. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ229 · Cited by 91 · cited 1×
“47% over a median of 3 years in 1 cohort.(2,3)”
BackgroundSato, T., Yagishita, N., Tamaki, K., Inoue, E., Hasegawa, D., Nagasaka, M., Suzuki, H., Araya, N., Coler-Reilly, A., Hasegawa, Y., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01651 · Cited by 68 · cited 3×
“The prognostic use of biomarkers of disease activity, especially CSF cytokines, has recently been published and may become an additional decision-making tool.(5)”
BackgroundInfluentialSelf-citationTsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1212-4 · Cited by 33 · cited 1×
“Although interferon-α has been licensed for the treatment of HAM/TSP in Japan since January 2000 (whereas prednisolone is not licensed there), in a recent survey, only 2–3% of patients with HAM/TSP in Japan are currently treated with interferon.(8) The panel concluded that the quality of the evidence on efficacy was l…”
ResultSelf-citationAdonis, A., & Taylor, G. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157132 · Cited by 14 · cited 1×
“It is helpful to use more than 1 clinical measure: for example, in patients with HAM/TSP, the 10-m timed walk has been shown to detect change but underestimate fatigue, which is identified with the 6-minute timed walk.(7)”
MethodSelf-citation
Research works printed but not linked: 2
- European Centre for Disease Prevention and Control. Geographical Distribution of Areas with a High Prevalence of HTLV-1 Infection. Stockholm, Sweden: ECDC; 2015.
- World Health Organisation. WHO diagnostic guidelines of HAM. Weekly Epidemiological Rec 1989;49:382–383.
Cited by
Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection
Legrand, N., McGregor, S., Bull, R. A., Bajis, S., Valencia, B. M., Ronnachit, A., Einsiedel, L. J., Gessain, A., Kaldor, J. M., & Martinello, M. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-21 · Cited by 96
Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview
Marino‐Merlo, F., Balestrieri, E., Matteucci, C., Mastino, A., Grelli, S., & Macchi, B. (2020) · Pathogens · doi:10.3390/pathogens9050342 · Cited by 49
Rosadas, C., Assone, T., Yamashita, M., Adonis, A., Puccioni‐Sohler, M., Santos, M., Paiva, A., Casseb, J., de Oliveira, A. C. P., & Taylor, G. P. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008761 · Cited by 45
“However, the consensus view is that sustained immunosuppression may be beneficial for HAM/TSP patients [50].”
BackgroundSelf-citationYamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses · doi:10.3390/v14010136 · Cited by 31
Self-citationCurrent Perspectives in Human T-Cell Leukemia Virus Type 1 Infection and Its Associated Diseases
Miura, M., Naito, T., & Saito, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.867478 · Cited by 34
Metadata
- Authors
- Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y.
- Affiliations
- Laboratory for Clinical Research in Neuroinfections (AA), Evandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, Brazil; Section of Immunology of Infection (CRMB), Department of Infectious Disease, Imperial College London, United Kingdom; Faculdade de Medicina da Universidade de São Paulo/Institute of Tropical Medicine of Sao Paulo (JC), Brazil; Instituto de Medicina Tropical “Alexander von Humboldt” (EG), Universidad Peruana Cayetano Heredia, Lima, Peru; Viral Immunology...
- Universidade Federal do Rio de Janeiro (BR)
- Corresponding author
- Taylor, Graham P.
- ORCID
- Venue
- Neurology Clinical Practice
- Published
- 2021-02
- Volume
- 11
- Issue
- 1
- Pages
- 49-56
- ISSN
- 2163-0402 (ISSN-L)
- 2163-0933
- PMC
- PMC8101298
- OpenAlex
- W3012056254
- Cited by
- 87
- References
- 6
- Citations by year
- 2026: 16 · 2025: 7 · 2024: 18 · 2023: 20 · 2022: 12 · 2021: 10
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Neurology Clinical Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (207477/Z/17/Z, 100291/Z/12/Z)
- Medical Research Council (K019090, MR/K019090/1)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Surgery › Cervical and Thoracic Myelopathy
- Keywords
- HAM/TSP, tropical spastic paraparesis, disease-modifying therapy, methylprednisolone pulse therapy, antiretroviral therapy, interferon-alpha, clinical outcomes, treatment guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019. https://app.cochat.ai/papers/10.1212/cpj.0000000000000832
- The paper
- Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y. (2021). Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019. Neurology Clinical Practice. https://doi.org/10.1212/cpj.0000000000000832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
